Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 11/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SIK1 | P57059 | 2/20 | 0.43 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.43 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2668063 | 0.90 | HPGD (0.52) | FGFR1MEN1KMT2AHPGDSIK1 | |
| SCHEMBL8233271 | 0.87 | FGFR1 (0.46) | FGFR1MEN1KMT2AHPGDSIK1 | |
| SCHEMBL2666424 | 0.87 | FGFR1 (0.46) | FGFR1MEN1KMT2AHPGDSIK1 | |
| SCHEMBL2652008 | 0.87 | FGFR1 (0.46) | FGFR1MEN1KMT2AHPGDSIK1 | |
| SCHEMBL12415695 | 0.86 | FGFR1 (0.45) | FGFR1MEN1KMT2AHPGDSIK1 | |
| SCHEMBL12415697 | 0.86 | FGFR1 (0.45) | FGFR1MEN1KMT2AHPGDSIK1 | |
| SCHEMBL13002369 | 0.86 | HPGD (0.57) | FGFR1HPGDALDH1A1 | |
| SCHEMBL12716015 | 0.85 | FGFR1 (0.44) | FGFR1MEN1KMT2AHPGDSIK1 | |
| SCHEMBL1617249 | 0.84 | KDR (0.52) | FGFR1HPGD | |
| SCHEMBL1616872 | 0.84 | KDR (0.52) | FGFR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923464-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-04-12 | — | — | US | disclosed |
| US-7923464-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-04-12 | — | — | US | disclosed |
| US-7923464-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-04-12 | — | — | US | disclosed |
| WO-2010055124-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| EP-1996556-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2009-11-18 | — | — | EP | disclosed |
| US-20090048321-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA-Alpha Receptor Complex | ANIONA APS (DK) | 2009-02-19 | — | — | US | disclosed |
| US-20090048321-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA-Alpha Receptor Complex | ANIONA APS (DK) | 2009-02-19 | — | — | US | disclosed |
| US-20090048321-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA-Alpha Receptor Complex | ANIONA APS (DK) | 2009-02-19 | — | — | US | disclosed |
| EP-1996556-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NeuroSearch A/S (DK) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007065864-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065864-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048321-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA-Alpha Receptor Complex | GABRB1, GABRB2, GABRB3 | FGFR1 3792/4885MEN1 4303/4885KMT2A 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.